Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$9.12 USD

9.12
4,101,961

-0.23 (-2.46%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $9.06 -0.06 (-0.66%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Sanghamitra Saha headshot

Here's How Americans Are Regaining Confidence: 5 Picks

U.S. consumer confidence gained in May and beat the expectations of economists polled by Dow Jones.

    Mark Vickery headshot

    Pre-Markets Race Higher on Vaccine Hopes

    Chief among positives for the market is a new vaccine candidate for COVID-19 from Novavax (NVAX), which is launching its human trials in Australia.

    Economic Data Deluge

    Economic Data Deluge

    Kinjel Shah headshot

    Coronavirus Vaccine Efforts Continue, Novavax Begins Human Trial

    As several pharma/biotech companies speed up efforts to make a vaccine for COVID-19, Novavax (NVAX) begins human testing of its candidate, NVX-CoV2373.

    Zacks.com headshot

    Novavax Begins Clinical Study for Coronavirus Vaccine

    Novavax (NVAX) enrolls the first set of participants in a phase I/II clinical study for evaluating its coronavirus vaccine candidate, NVX-CoV2373.

    Tirthankar Chakraborty headshot

    2 Top Factors Buoy Wall Street Since Memorial Day: 5 Picks

    As optimism surrounding a coronavirus vaccine and consumer activity begin to pick up, Wall Street is expected to trade higher.

    Sanghamitra Saha headshot

    Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up

    Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.

    Ritujay Ghosh headshot

    Coronavirus Vaccine Development Gathers Steam: 4 Winners

    Many biotech companies are coming up with impressive reports on their development of drugs, vaccines and therapies for COVID-19.

    Jeremy Mullin headshot

    S&P Set to Open Above 3000

    Bulls start the week trying to break the 200-day moving average.

    Sweta Jaiswal, FRM headshot

    Is Moderna Winning the COVID-19 Vaccine Race? ETFs to Gain

    Moderna has presented positive interim data from a phase I study evaluating its mRNA-based coronavirus vaccine candidate.

    Sanghamitra Saha headshot

    Wining ETF Areas of Last Week

    Though last week was not upbeat for Wall Street, these ETFs breezed past Wall Street.

    Sanghamitra Saha headshot

    Leveraged ETFs of Last Week

    These leveraged ETFs were outperformers last week.

    Is Novavax (NVAX) Stock Outpacing Its Medical Peers This Year?

    Is (NVAX) Outperforming Other Medical Stocks This Year?

    Novovax (NVAX) Surges on CEPI Funding for Coronavirus Vaccine

    Novovax (NVAX) is set to receive funding of up to $388 million from CEPI to support clinical development and scaling up of production of its coronavirus vaccine candidate.

    Sweta Jaiswal, FRM headshot

    Novavax Soars on Coronavirus Vaccine Funding: ETFs to Gain

    Novavax received funding for the coronavirus vaccine and also delivered better-than-expected Q1 results resulting in a stock rally in yesterday's trading session.

    Novavax (NVAX) Reports Q1 Loss, Lags Revenue Estimates

    Novavax (NVAX) delivered earnings and revenue surprises of 13.43% and -3.51%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

    Why Earnings Season Could Be Great for Novavax (NVAX)

    Novavax (NVAX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    Emergent (EBS) Earnings and Revenues Beat Estimates in Q1

    Emergent's (EBS) earnings and revenues surpass estimates in the first quarter of 2020. The company reaffirms its guidance for the ongoing year.

    Novavax (NVAX) Dips More Than Broader Markets: What You Should Know

    Novavax (NVAX) closed at $18.13 in the latest trading session, marking a -1.52% move from the prior day.

    Novavax (NVAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

    Novavax (NVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    The Zacks Analyst Blog Highlights: Moderna, Johnson & Johnson, Sanofi and Novavax

    The Zacks Analyst Blog Highlights: Moderna, Johnson & Johnson, Sanofi and Novavax

    3 Stocks to Benefit From Race to Develop Coronavirus Vaccines

    Pharmaceutical companies and scientists are relentlessly working on developing coronavirus vaccines and the progress in trails has helped stocks to rally.

    Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?

    During Novavax's (NVAX) upcoming Q1 earnings call, investor focus will be on the company's progress with its seasonal influenza vaccine candidate, NanoFlu, and the COVID-19 vaccine candidate.

    Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

    In the latest trading session, Novavax (NVAX) closed at $21.37, marking a -0.74% move from the previous day.

    Vaxart Up on Pre-Clinical Data on Coronavirus Vaccine Candidates

    Vaxart's (VXRT) several COVID-19 vaccine candidates generate immune responses in pre-clinical studies. Stock rises.